{"id":834434,"date":"2025-04-07T08:27:25","date_gmt":"2025-04-07T12:27:25","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/tuhura-biosciences-inc-appoints-dr-bertrand-le-bourdonnec-as-executive-vice-president-head-of-drug-discovery-early-development-and-program-management\/"},"modified":"2025-04-07T08:27:25","modified_gmt":"2025-04-07T12:27:25","slug":"tuhura-biosciences-inc-appoints-dr-bertrand-le-bourdonnec-as-executive-vice-president-head-of-drug-discovery-early-development-and-program-management","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tuhura-biosciences-inc-appoints-dr-bertrand-le-bourdonnec-as-executive-vice-president-head-of-drug-discovery-early-development-and-program-management\/","title":{"rendered":"TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n Proven 20-year career in drug discovery and development track record leading to 12 pre-clinical\/clinical candidates and 7 investigational new drug \/ clinical trial applications<\/i>\n <\/p>\n

\n Extensive knowledge in the biochemistry\u00a0and\u00a0pharmacology\u00a0of\u00a0the Delta Opioid Receptor\u00a0(DOR),\u00a0the\u00a0primary\u00a0target in\u00a0TuHURA’s\u00a0Antibody Drug\u00a0Conjugate\u00a0(ADC) and Antibody Peptide Conjugate (APC) technology platform<\/i>\n <\/p>\n

\n Inventor\u00a0of\u00a0first-in-class\u00a0spirocyclic\u00a0DOR\u00a0agonists\u00a0as\u00a0potential\u00a0analgesics;\u00a0clinical- stage products licensed to Pfizer<\/i>\n <\/p>\n

\n Led\u00a0the\u00a0benevopran\u00a0opioid-induced\u00a0bowel\u00a0dysfunction\u00a0program\u00a0to\u00a0positive Phase IIb results: key value inflection point resulting in the acquisition of Adolor Corporation by Cubist Pharmaceuticals<\/i>\n <\/p>\n

\n
\n TAMPA, Fla.<\/span>
\n <\/span>, April 7, 2025<\/span><\/span> \/PRNewswire\/ — TuHURA Biosciences, Inc.\u00a0<\/b>(NASDAQ: HURA) (“TuHURA”), a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced the appointment of Bertrand Le Bourdonnec, PhD as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management.<\/p>\n

\n

\n
\n \"Bertrand
\n <\/a>\n <\/p>\n<\/p><\/div>\n

Dr. Le\u00a0Bourdonnec is a seasoned biotech executive with broad scientific and leadership experience across all stages of drug discovery through clinical development and regulatory approval. He has successfully led R&D programs in multiple therapeutic areas including oncology, pain, gastro- intestinal disorders, infectious diseases\u00a0and neurodegenerative diseases. He is a noted expert on opioid receptor biochemistry and pharmacology and\u00a0has\u00a0discovered\u00a0and\u00a0developed\u00a0several drugs targeting various members of the opioid receptor family.<\/p>\n

“We are excited to add Dr. Le\u00a0Bourdonnec to\u00a0the\u00a0TuHURA\u00a0team.\u00a0His\u00a0expertise\u00a0in\u00a0the\u00a0pharmacology and biochemistry of the Delta Opioid Receptor (DOR) is a perfect addition to lead the discovery effort for our novel ADCs and APCs targeting the DOR on myeloid derived suppressor cells (MDSCs). Having successfully developed\u00a0drugs that\u00a0stimulate\u00a0the\u00a0DOR,\u00a0he\u00a0is uniquely positioned to develop DOR inhibitors\u00a0that seek to block the immune suppressing effects of MDSCs on the tumor microenvironment.” commented James Bianco,\u00a0M.D.,\u00a0President\u00a0and\u00a0Chief\u00a0Executive\u00a0Officer of TuHURA.<\/p>\n

Dr. Le\u00a0Bourdonnec added, “I am thrilled to join the TuHURA team at this pivotal time in the Company’s evolution and look forward to playing an important role in driving our pipeline forward with the goal of addressing patient unmet medical needs potentially transforming the treatment paradigm for people battling cancer.”<\/p>\n

Prior\u00a0to\u00a0joining TuHURA,\u00a0Dr.\u00a0Le\u00a0Bourdonnec\u00a0served as\u00a0the\u00a0Chief Scientific\u00a0Officer and\u00a0Scientific\u00a0Advisor for HDAX Therapeutics, a biotechnology company pioneering a novel approach to targeting HDAC6 for the discovery and development of breakthrough therapeutics for high unmet medical needs. During\u00a0his\u00a0tenure\u00a0at\u00a0HDAX,\u00a0Dr.\u00a0Le\u00a0Bourdonnec\u00a0was\u00a0responsible for developing a research strategy and managing discovery activities that contributed to the company’s completion of an oversubscribed seed round in September 2024<\/span>. Prior to HDAX Therapeutics, he served as VP, Chemical, Pharmaceutical & Pre- Clinical Sciences at\u00a0Deciphera Pharmaceuticals where he led a team of 31 scientists and managed Medicinal Chemistry, Pharmaceutical Sciences,\u00a0ADME\/DMPK & Toxicology activities supporting the identification of novel kinase inhibitors designed using Deciphera’s proprietary kinase switch control platform.\u00a0He was also responsible for managing non-clinical development activities for Deciphera’s clinical stage products. Prior to that, he led several R&D functions at Yumanity\u00a0Therapeutics\u00a0and\u00a0contributed\u00a0to\u00a0the\u00a0company’s\u00a0growth\u00a0from early\u00a0start-up to\u00a0a\u00a0clinical\u00a0stage\u00a0organization.\u00a0Earlier\u00a0in\u00a0his\u00a0career,\u00a0Dr.\u00a0Le\u00a0Bourdonnec\u00a0served\u00a0as\u00a0the VP, Discovery Chemistry & Pharmaceutical Research at Cubist Pharmaceuticals, where he led a department of 87 chemists (57 internal; 30 external) across different functions including Medicinal Chemistry, Computational Chemistry, Analytical Chemistry, Process Chemistry Research, Formulation Research, Chemistry Outsourcing, Bioinformatics, Cheminformatics, Compound Management and High-Throughput Screening.\u00a0He began his industry career at\u00a0Adolor Corporation (acquired by Cubist Pharmaceuticals in Oct 2011<\/span>) and held a number of positions, culminating as the Senior Director, Program Management and Discovery. During his time at Adolor, he played an integral role in\u00a0many\u00a0value-driving\u00a0accomplishments,\u00a0including\u00a0the\u00a0invention of\u00a0first-in-class\u00a0spirocyclic\u00a0delta opioid\u00a0receptor\u00a0(DOR)\u00a0agonists as\u00a0potential\u00a0analgesics (ADL5859 & ADL5747) which were licensed to Pfizer for $30M<\/span> upfront.<\/p>\n

Dr.\u00a0Le\u00a0Bourdonnec\u00a0holds\u00a0a\u00a0Chemical Engineering\u00a0degree\u00a0and\u00a0a\u00a0PhD\u00a0in\u00a0Organic Chemistry\u00a0from\u00a0the University of Lille<\/span> (France<\/span>). He also completed a post-doctoral fellowship in the US in the laboratory of Professor Portoghese at the University of Minnesota<\/span>.<\/p>\n

\n About TuHURA\u00a0Biosciences,\u00a0Inc.<\/b>\n <\/p>\n

TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 registration-stage immuno-oncology company\u00a0developing\u00a0novel\u00a0technologies\u00a0to\u00a0overcome\u00a0primary and\u00a0acquired\u00a0resistance\u00a0to\u00a0cancer immunotherapy, two of the most common reasons cancer\u00a0immunotherapies\u00a0fail\u00a0to\u00a0work\u00a0or\u00a0stop working in the majority of patients with cancer.<\/p>\n

TuHURA’s lead innate immune agonist candidate, IFx-2.0, is designed to overcome primary resistance\u00a0to\u00a0checkpoint\u00a0inhibitors.\u00a0TuHURA is\u00a0preparing\u00a0to\u00a0initiate\u00a0a\u00a0single\u00a0randomized\u00a0placebo-controlled Phase\u00a03\u00a0registration\u00a0trial\u00a0of\u00a0IFx-2.0 administered\u00a0as\u00a0an\u00a0adjunctive\u00a0therapy to\u00a0Keytruda\u00ae (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma.<\/p>\n

In addition to its innate immune agonist candidates, TuHURA is leveraging its Delta Opioid Receptor technology to\u00a0develop\u00a0first-in-class bi-specific\u00a0ADCs and APCs targeting Myeloid\u00a0Derived Suppressor Cells to inhibit their immune-suppressing\u00a0effects on\u00a0the tumor\u00a0microenvironment\u00a0to prevent\u00a0T\u00a0cell\u00a0exhaustion\u00a0and\u00a0acquired\u00a0resistance\u00a0to\u00a0checkpoint\u00a0inhibitors\u00a0and\u00a0cellular\u00a0therapies.<\/p>\n

For more information, please visit\u00a0tuhurabio.com<\/a>\u00a0and connect with TuHURA on\u00a0Facebook<\/a>,\u00a0X<\/a>, and LinkedIn.<\/a><\/p>\n

\n Forward-Looking Statements<\/b>\n <\/p>\n

This press release contains certain “forward-looking statements” within the meaning of, and subject to the safe harbor created by, Section 27A of the Securities Act, Section 21E of the Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, development programs, future plans and strategies, projections, anticipated events and other future conditions. In some cases you can identify\u00a0these\u00a0statements\u00a0by\u00a0forward-looking\u00a0words\u00a0such\u00a0as\u00a0“believe,”\u00a0“may,” “will,”\u00a0“estimate,” “continue,” “anticipate,” “intend,” “could,” “should,” “would,” “project,” “plan,” “expect,” “goal,” “seek,” “future,” “likely” or the negative or plural of these words or similar expressions. Examples of such forward-looking statements include, but are not limited to, statements regarding TuHURA’s IFx-Hu2.0\u00a0product candidate and anticipated Phase 3\u00a0trial, its\u00a0development program relating to its Delta Opioid Receptor technology, and any developments or results in connection therewith and the anticipated regulatory pathway and timing of the foregoing development programs, studies and trials. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in these forward-looking statements. Factors that could cause actual results to differ materially from these forward-looking statements are described in detail in our Annual<\/p>\n

Report on Form 10-K filed on March 31, 2025<\/span> and our other filings with the SEC, which are available at www.sec.gov.<\/a><\/p>\n

The\u00a0forward-looking\u00a0statements\u00a0and other\u00a0information\u00a0contained\u00a0in\u00a0this\u00a0press\u00a0release are\u00a0made as\u00a0of\u00a0the\u00a0date\u00a0hereof,\u00a0and\u00a0TuHURA does\u00a0not\u00a0undertake any\u00a0obligation\u00a0to\u00a0update\u00a0publicly or\u00a0revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.<\/p>\n

Investor Contact:
Dan Dearborn<\/span> (813) 875-6600
ddearborn@tuhurabio.com<\/a>\u00a0<\/p>\n

\n

\n
\n \"(PRNewsfoto\/Kintara
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/tuhura-biosciences-inc-appoints-dr-bertrand-le-bourdonnec-as-executive-vice-president-head-of-drug-discovery-early-development-and-program-management-302421980.html<\/a><\/p>\n

SOURCE TuHURA Biosciences, Inc.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire Proven 20-year career in drug discovery and development track record leading to 12 pre-clinical\/clinical candidates and 7 investigational new drug \/ clinical trial applications Extensive knowledge in the biochemistry\u00a0and\u00a0pharmacology\u00a0of\u00a0the Delta Opioid Receptor\u00a0(DOR),\u00a0the\u00a0primary\u00a0target in\u00a0TuHURA’s\u00a0Antibody Drug\u00a0Conjugate\u00a0(ADC) and Antibody Peptide Conjugate (APC) technology platform Inventor\u00a0of\u00a0first-in-class\u00a0spirocyclic\u00a0DOR\u00a0agonists\u00a0as\u00a0potential\u00a0analgesics;\u00a0clinical- stage products licensed to Pfizer Led\u00a0the\u00a0benevopran\u00a0opioid-induced\u00a0bowel\u00a0dysfunction\u00a0program\u00a0to\u00a0positive Phase IIb results: key value inflection point resulting in the acquisition of Adolor Corporation by Cubist Pharmaceuticals TAMPA, Fla. , April 7, 2025 \/PRNewswire\/ — TuHURA Biosciences, Inc.\u00a0(NASDAQ: HURA) (“TuHURA”), a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced the appointment of Bertrand Le Bourdonnec, PhD as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management. Dr. Le\u00a0Bourdonnec is … <\/p>\n

Continue reading “TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-834434","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nTuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tuhura-biosciences-inc-appoints-dr-bertrand-le-bourdonnec-as-executive-vice-president-head-of-drug-discovery-early-development-and-program-management\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire Proven 20-year career in drug discovery and development track record leading to 12 pre-clinical\/clinical candidates and 7 investigational new drug \/ clinical trial applications Extensive knowledge in the biochemistry\u00a0and\u00a0pharmacology\u00a0of\u00a0the Delta Opioid Receptor\u00a0(DOR),\u00a0the\u00a0primary\u00a0target in\u00a0TuHURA’s\u00a0Antibody Drug\u00a0Conjugate\u00a0(ADC) and Antibody Peptide Conjugate (APC) technology platform Inventor\u00a0of\u00a0first-in-class\u00a0spirocyclic\u00a0DOR\u00a0agonists\u00a0as\u00a0potential\u00a0analgesics;\u00a0clinical- stage products licensed to Pfizer Led\u00a0the\u00a0benevopran\u00a0opioid-induced\u00a0bowel\u00a0dysfunction\u00a0program\u00a0to\u00a0positive Phase IIb results: key value inflection point resulting in the acquisition of Adolor Corporation by Cubist Pharmaceuticals TAMPA, Fla. , April 7, 2025 \/PRNewswire\/ — TuHURA Biosciences, Inc.\u00a0(NASDAQ: HURA) (“TuHURA”), a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced the appointment of Bertrand Le Bourdonnec, PhD as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management. Dr. Le\u00a0Bourdonnec is … Continue reading "TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/tuhura-biosciences-inc-appoints-dr-bertrand-le-bourdonnec-as-executive-vice-president-head-of-drug-discovery-early-development-and-program-management\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-07T12:27:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/2657908\/Tuhura_Biosciences_Inc_Bert_Le_Bourdonnec_ID_060b81c9d124.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tuhura-biosciences-inc-appoints-dr-bertrand-le-bourdonnec-as-executive-vice-president-head-of-drug-discovery-early-development-and-program-management\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tuhura-biosciences-inc-appoints-dr-bertrand-le-bourdonnec-as-executive-vice-president-head-of-drug-discovery-early-development-and-program-management\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management\",\"datePublished\":\"2025-04-07T12:27:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tuhura-biosciences-inc-appoints-dr-bertrand-le-bourdonnec-as-executive-vice-president-head-of-drug-discovery-early-development-and-program-management\\\/\"},\"wordCount\":1211,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tuhura-biosciences-inc-appoints-dr-bertrand-le-bourdonnec-as-executive-vice-president-head-of-drug-discovery-early-development-and-program-management\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2657908\\\/Tuhura_Biosciences_Inc_Bert_Le_Bourdonnec_ID_060b81c9d124.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tuhura-biosciences-inc-appoints-dr-bertrand-le-bourdonnec-as-executive-vice-president-head-of-drug-discovery-early-development-and-program-management\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tuhura-biosciences-inc-appoints-dr-bertrand-le-bourdonnec-as-executive-vice-president-head-of-drug-discovery-early-development-and-program-management\\\/\",\"name\":\"TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tuhura-biosciences-inc-appoints-dr-bertrand-le-bourdonnec-as-executive-vice-president-head-of-drug-discovery-early-development-and-program-management\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tuhura-biosciences-inc-appoints-dr-bertrand-le-bourdonnec-as-executive-vice-president-head-of-drug-discovery-early-development-and-program-management\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2657908\\\/Tuhura_Biosciences_Inc_Bert_Le_Bourdonnec_ID_060b81c9d124.jpg\",\"datePublished\":\"2025-04-07T12:27:25+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tuhura-biosciences-inc-appoints-dr-bertrand-le-bourdonnec-as-executive-vice-president-head-of-drug-discovery-early-development-and-program-management\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tuhura-biosciences-inc-appoints-dr-bertrand-le-bourdonnec-as-executive-vice-president-head-of-drug-discovery-early-development-and-program-management\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tuhura-biosciences-inc-appoints-dr-bertrand-le-bourdonnec-as-executive-vice-president-head-of-drug-discovery-early-development-and-program-management\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2657908\\\/Tuhura_Biosciences_Inc_Bert_Le_Bourdonnec_ID_060b81c9d124.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2657908\\\/Tuhura_Biosciences_Inc_Bert_Le_Bourdonnec_ID_060b81c9d124.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tuhura-biosciences-inc-appoints-dr-bertrand-le-bourdonnec-as-executive-vice-president-head-of-drug-discovery-early-development-and-program-management\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/tuhura-biosciences-inc-appoints-dr-bertrand-le-bourdonnec-as-executive-vice-president-head-of-drug-discovery-early-development-and-program-management\/","og_locale":"en_US","og_type":"article","og_title":"TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management - Market Newsdesk","og_description":"PR Newswire Proven 20-year career in drug discovery and development track record leading to 12 pre-clinical\/clinical candidates and 7 investigational new drug \/ clinical trial applications Extensive knowledge in the biochemistry\u00a0and\u00a0pharmacology\u00a0of\u00a0the Delta Opioid Receptor\u00a0(DOR),\u00a0the\u00a0primary\u00a0target in\u00a0TuHURA’s\u00a0Antibody Drug\u00a0Conjugate\u00a0(ADC) and Antibody Peptide Conjugate (APC) technology platform Inventor\u00a0of\u00a0first-in-class\u00a0spirocyclic\u00a0DOR\u00a0agonists\u00a0as\u00a0potential\u00a0analgesics;\u00a0clinical- stage products licensed to Pfizer Led\u00a0the\u00a0benevopran\u00a0opioid-induced\u00a0bowel\u00a0dysfunction\u00a0program\u00a0to\u00a0positive Phase IIb results: key value inflection point resulting in the acquisition of Adolor Corporation by Cubist Pharmaceuticals TAMPA, Fla. , April 7, 2025 \/PRNewswire\/ — TuHURA Biosciences, Inc.\u00a0(NASDAQ: HURA) (“TuHURA”), a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced the appointment of Bertrand Le Bourdonnec, PhD as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management. Dr. Le\u00a0Bourdonnec is … Continue reading \"TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/tuhura-biosciences-inc-appoints-dr-bertrand-le-bourdonnec-as-executive-vice-president-head-of-drug-discovery-early-development-and-program-management\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-07T12:27:25+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/2657908\/Tuhura_Biosciences_Inc_Bert_Le_Bourdonnec_ID_060b81c9d124.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tuhura-biosciences-inc-appoints-dr-bertrand-le-bourdonnec-as-executive-vice-president-head-of-drug-discovery-early-development-and-program-management\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tuhura-biosciences-inc-appoints-dr-bertrand-le-bourdonnec-as-executive-vice-president-head-of-drug-discovery-early-development-and-program-management\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management","datePublished":"2025-04-07T12:27:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tuhura-biosciences-inc-appoints-dr-bertrand-le-bourdonnec-as-executive-vice-president-head-of-drug-discovery-early-development-and-program-management\/"},"wordCount":1211,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tuhura-biosciences-inc-appoints-dr-bertrand-le-bourdonnec-as-executive-vice-president-head-of-drug-discovery-early-development-and-program-management\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2657908\/Tuhura_Biosciences_Inc_Bert_Le_Bourdonnec_ID_060b81c9d124.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tuhura-biosciences-inc-appoints-dr-bertrand-le-bourdonnec-as-executive-vice-president-head-of-drug-discovery-early-development-and-program-management\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/tuhura-biosciences-inc-appoints-dr-bertrand-le-bourdonnec-as-executive-vice-president-head-of-drug-discovery-early-development-and-program-management\/","name":"TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tuhura-biosciences-inc-appoints-dr-bertrand-le-bourdonnec-as-executive-vice-president-head-of-drug-discovery-early-development-and-program-management\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tuhura-biosciences-inc-appoints-dr-bertrand-le-bourdonnec-as-executive-vice-president-head-of-drug-discovery-early-development-and-program-management\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2657908\/Tuhura_Biosciences_Inc_Bert_Le_Bourdonnec_ID_060b81c9d124.jpg","datePublished":"2025-04-07T12:27:25+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tuhura-biosciences-inc-appoints-dr-bertrand-le-bourdonnec-as-executive-vice-president-head-of-drug-discovery-early-development-and-program-management\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/tuhura-biosciences-inc-appoints-dr-bertrand-le-bourdonnec-as-executive-vice-president-head-of-drug-discovery-early-development-and-program-management\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tuhura-biosciences-inc-appoints-dr-bertrand-le-bourdonnec-as-executive-vice-president-head-of-drug-discovery-early-development-and-program-management\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/2657908\/Tuhura_Biosciences_Inc_Bert_Le_Bourdonnec_ID_060b81c9d124.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/2657908\/Tuhura_Biosciences_Inc_Bert_Le_Bourdonnec_ID_060b81c9d124.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tuhura-biosciences-inc-appoints-dr-bertrand-le-bourdonnec-as-executive-vice-president-head-of-drug-discovery-early-development-and-program-management\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/834434","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=834434"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/834434\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=834434"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=834434"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=834434"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}